In 1992 in El Paso, TX a randomized, double-blind, placebo controlled study of subjects spring air mattresses (n=130) with allergic rhinitis in 1992-1993 was conducted. the average ige level of the placebo treated subjects air remained essentially flat, while the average ige level for active treated subjects was reduced significantly from baseline to day 30.7 in 1993 in el paso, tx, valid subjects (n=66) returned a second set of symptom diaries which they had completed for days 365 to 395 (the same period, one year after the first set of symptom diaries). the active group mattresses had mean symptom scores showing statistically significant decreases from 1992 to 1993. the placebo group had increased symptoms in 1993. (the relevant pollen counts at the study site in 1993 were much higher than in 1992, leading to expectation spring of higher air symptoms.)7

in 1990 study in san diego, ca the 5 mattresses active subjects with allergic rhinitis had a lowered total serum ige from day 0 to day 90 while 4 placebo subjects, (2 with allergic rhinitis, 1 with asthma and 1 with both), had flat spring or increased ige levels.4 in a randomized, double-blind, placebo controlled study of symptoms and serum ige levels in san diego, ca in air mid-1991, subjects had allergic rhinitis and/or asthma. serum was drawn at day 0 and day 30. seven of the 10 active treated subjects had a reduction in total serum ige levels. in 10 placebo treated subjects, 5 had levels of total serum ige that stayed the same (plus or minus 5%), 3 decreased and 2 increased.5 statistical analysis of the open-label study as well as the double-blind randomized placebo controlled study have shown a significant effect of vitamin b12 in lowering serum ige concentrations.

all of the active b12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. wilcoxon-rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for ige reductions. in 1992, the above mentioned data from 1988 on were presented by dr. o''connor to the fda. mattresses the fda panel acknowledged the safety of the treatment. the panel seemed to be in agreement that the statistics indicated a significant reduction in ige and that a quantitative drop in symptoms was demonstrated. in 1992, belen anibarro, md, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. the test was repeated after premedication with 1.5 mg of oral cyanocobalamin. in four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

©2003 www.mattress-air-beds.com All rights reserved.